The effects of olanzapine on sensory gating in healthy participants [1]

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 187-189

  Carroll, Christine A ^a   O'Donnell, Brian F ^a   Shekhar, Anantha ^b   Hetrick, William P ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; MARKER; MONOAMINE; NEUROTRANSMITTER; OLANZAPINE; PLACEBO; PROTEIN P50;

AUDITORY STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; LETTER; MENTAL DISEASE; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTRANSMISSION; NORMAL HUMAN; ORBICULARIS OCULI MUSCLE; PREPULSE INHIBITION; PRIORITY JOURNAL; REGULATORY MECHANISM; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SENSORY SYSTEM; STARTLE REFLEX;

EID: 0346786358     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00149-X     Document Type: Letter

References (10)

1. Abduljawad K.A.J., Langley R.W., Bradshaw C.M., Sczabadi W. Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. Journal of Psychopharmacology. 12:1998;239-245.
2. Adler L.E., Hoffer L., Nagamoto H.T., Waldo M.C., Kisley M.A., Griffith J.M. Yohimbine impairs P50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 10(4):1994;249-257.
3. Baker N.J., Staunton M., Adler L.E., Gerhardt G.A., Drebing C., Waldo M., Nagamoto H., Freedman R. Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups. Biological Psychiatry. 27(5):1990;519-528.
4. Bakshi V.P., Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201.
5. Braff D.L., Swerdlow N.R., Geyer M.A. Gating and habituation deficits in the schizophrenia disorders. Clinical Neuroscience. 3:1995;131-139.
6. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.M., Drebing C., Nagamoto H., Bickford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophrenia Bulletin. 13(4):1987;669-678.
7. Hetrick W.P., Sandman C.A., Bunney W.E. Jr., Jin Y., Potkin S.G., White M.H. Gender differences in gating of the auditory evoked potential in normal subjects. Biological Psychiatry. 39(1):1996;51-58.
8. Kumari V., Soni W., Sharma T. Normalization of information processing deficits in schizophrenia with clozapine. The American Journal of Psychiatry. 156(7):1999;1046-1051.
9. Light G.A., Malaspina D.M., Geyer M.A., Luber B.M., Coleman E.A., Sackeim H.A., Braff D.L. Amphetamine disrupts P50 suppression in normal subjects. Biological Psychiatry. 46:1999;990-996.
10. van Berckel B.N., Oranje B., van Ree J.M., Verbaten M.N., Kahn R.S. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects. Psychopharmacologia. 137(3):1998;271-281.